{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T00:15:03Z","timestamp":1789172103131,"version":"build-2803163510"},"reference-count":33,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"Technology Innovation Project of China Academy of Chinese Medical Sciences","award":["No. CI2026A01810"],"award-info":[{"award-number":["No. CI2026A01810"]}]},{"name":"Hospital Capability Enhancement Project of Xiyuan Hospital, CACMS","award":["No. XYZX0201-22"],"award-info":[{"award-number":["No. XYZX0201-22"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No. 82174461"],"award-info":[{"award-number":["No. 82174461"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Integr Cancer Ther"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Our previous studies showed that Quxie capsule (QX) remarkably prolongs the survival of patients with advanced colorectal cancer (CRC) and downregulates CT10 regulator of kinase (CRK) protein expression in responders. However, the underlying mechanism through which QX inhibits CRC invasion remains unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To elucidate the mechanism through which QX suppresses CRC invasion.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      The IC\n                      <jats:sub>50<\/jats:sub>\n                      values of QX and 5-fluorouracil (5-FU) were determined by CCK-8 assay to establish drug intervention concentrations. Flow cytometry, Transwell assays, and hematoxylin-eosin (HE) staining were used to evaluate the effects of QX and 5-FU combination on the proliferation, apoptosis, cell cycle, migration, invasion, and tube formation ability of CRC cells. Modulation of the CRK-RAC signaling pathway was analyzed by qRT-PCR and western blotting assay. For\n                      <jats:italic toggle=\"yes\">in vivo<\/jats:italic>\n                      validation assay, tumor-bearing nude mouse models were utilized to measure tumor volume, and HE staining, immunohistochemical assay were conducted to assess tumor proliferation and apoptosis. A sh-CRKL knockdown stable cell line was established to investigate the role of CRKL in CRC invasion through simultaneous\n                      <jats:italic toggle=\"yes\">in vitro<\/jats:italic>\n                      and\n                      <jats:italic toggle=\"yes\">in vivo<\/jats:italic>\n                      experiments.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Proteomics analysis identified Crk-like protein (CRKL) as a differentially expressed protein in CRC. In vitro experiments demonstrated that the combined treatment of QX (0.589 mg\/mL, 0.597 mg\/mL) with 5-FU (4.036 \u03bcg\/mL, 6.417 \u03bcg\/mL) could enhance the inhibition of the proliferation of CRC cells (HCT116 and SW620) and induced apoptosis (P &lt; 0.05), while significantly downregulating the CRKL-RAC signaling pathway activity. Knocking down the CRKL gene further confirmed that CRKL deficiency inhibits cancer cell invasion; in the CRKL-deficient model, the combination therapy of QX and 5-FU further enhanced the inhibitory effect on tumor progression (P &lt; 0.05). In vivo experiments also validated the efficacy of this combination therapy: compared with the monotherapy group, the combination of QX and 5-FU significantly inhibited tumor growth in tumor-bearing mice (P &lt; 0.05) and was accompanied by downregulation of key proteins in the CRKL-RAC signaling pathway (P &lt; 0.05).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>QX inhibits CRC invasion by downregulating CRKL protein expression and modulating the CRK-RAC signaling pathway; this finding provides a mechanistic basis for validating the clinical efficacy of QX.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/15347354261487221","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T23:53:31Z","timestamp":1788998011000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["The Mechanism Underlying Inhibition of Colorectal Cancer Invasion by Quxie Capsule Through CRK-RAC Signaling Pathway Regulation"],"prefix":"10.1177","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-0374-4662","authenticated-orcid":false,"given":"Jiang-yu","family":"Bian","sequence":"first","affiliation":[{"name":"Department of Oncology, Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-xing","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Oncology, Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin-feng","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Oncology, Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-fei","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Oncology, Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Oncology, Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,9,9]]},"reference":[{"issue":"1","key":"e_1_3_5_2_2","first-page":"1","article-title":"Cancer incidence and mortality in China,2016","volume":"2","author":"Zheng RS","year":"2022","unstructured":"Zheng RS, Zhang SW, Zeng HM, et al. Cancer incidence and mortality in China,2016. J Nati Cancer Cent. 2022;2(1):1-9.","journal-title":"J Nati Cancer Cent"},{"issue":"12","key":"e_1_3_5_3_2","first-page":"CD011044","article-title":"Chemotherapy and radiotherapy for advanced pancreatic cancer","volume":"12","author":"Haggstrom L","year":"2024","unstructured":"Haggstrom L, Chan WY, Nagrial A, et al. Chemotherapy and radiotherapy for advanced pancreatic cancer. Cochrane Database Syst Rev. 2024;12(12):CD011044.","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_5_4_2","doi-asserted-by":"publisher","DOI":"10.5603\/rpor.103136"},{"key":"e_1_3_5_5_2","doi-asserted-by":"publisher","DOI":"10.2147\/IJN.S466396"},{"key":"e_1_3_5_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2025.148082"},{"key":"e_1_3_5_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2025.120677"},{"issue":"05","key":"e_1_3_5_8_2","first-page":"715","article-title":"Theoretical analysis of the treatment of colorectal cancer with Tongyang method(J)","volume":"33","author":"Yang YF","year":"2009","unstructured":"Yang YF, Wang JB. Theoretical analysis of the treatment of colorectal cancer with Tongyang method(J). Journal of Zhejiang Chinese Medical University. 2009;33(05):715-716.","journal-title":"Journal of Zhejiang Chinese Medical University"},{"issue":"15","key":"e_1_3_5_9_2","first-page":"2114","article-title":"Discussion on the diagnosis and treatment ideas of colorectal cancer with the core pathogenesis of yang deficiency and yin excess","volume":"32","author":"Guo XY","year":"2023","unstructured":"Guo XY, Song Z, Xu Y, Wang FY, Yang YF. Discussion on the diagnosis and treatment ideas of colorectal cancer with the core pathogenesis of yang deficiency and yin excess. Journal of Modern Integrative Medicine. 2023;32(15):2114-2118.","journal-title":"Journal of Modern Integrative Medicine"},{"key":"e_1_3_5_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11655-017-2962-2"},{"key":"e_1_3_5_11_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00109-002-0370-2"},{"key":"e_1_3_5_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.jbchem.a021401"},{"key":"e_1_3_5_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/emboj\/cdf446"},{"key":"e_1_3_5_14_2","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.200712050"},{"key":"e_1_3_5_15_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M700823200"},{"key":"e_1_3_5_16_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M011238200"},{"key":"e_1_3_5_17_2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1399885"},{"key":"e_1_3_5_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jare.2023.07.007"},{"key":"e_1_3_5_19_2","doi-asserted-by":"publisher","DOI":"10.1177\/1534735419883687"},{"issue":"05","key":"e_1_3_5_20_2","first-page":"1119","article-title":"Traditional Chinese Medicine Combined with Chemotherapy in Treatment of Advanced Colorectal Cancer:A Systematic Review","volume":"36","author":"Miao WR","year":"2018","unstructured":"Miao WR, Liu NN, Zhu HR, Li Q. Traditional Chinese Medicine Combined with Chemotherapy in Treatment of Advanced Colorectal Cancer:A Systematic Review. Chinese Archives of Traditional Chinese Medicine. 2018;36(05):1119-1124.","journal-title":"Chinese Archives of Traditional Chinese Medicine"},{"issue":"07","key":"e_1_3_5_21_2","first-page":"804","article-title":"Analysis on Characteristics of Chinese Medicine Beneficiaries in Advanced Colorectal Cancer","volume":"39","author":"Xu YY","year":"2019","unstructured":"Xu YY, Sun LY, Zhang C, et al. Analysis on Characteristics of Chinese Medicine Beneficiaries in Advanced Colorectal Cancer. Chinese Journal of Integrated Traditional and Western Medicine. 2019;39(07):804-809.","journal-title":"Chinese Journal of Integrated Traditional and Western Medicine"},{"issue":"3","key":"e_1_3_5_22_2","first-page":"170","article-title":"Ginsenoside Rg1 improves anti-tumor efficacy of adoptive cell therapy by enhancing T cell effector functions","volume":"5","author":"Liu Y","year":"2023","unstructured":"Liu Y, An L, Yang C, Wang X, Huang R, Zhang X. Ginsenoside Rg1 improves anti-tumor efficacy of adoptive cell therapy by enhancing T cell effector functions. Blood Sci. 2023;5(3):170-179.","journal-title":"Blood Sci"},{"key":"e_1_3_5_23_2","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.20710"},{"key":"e_1_3_5_24_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-020-01741-5"},{"issue":"10","key":"e_1_3_5_25_2","first-page":"5473","article-title":"Crk promotes proliferation, migration, invasion of laryngeal squamous cell carcinoma","volume":"24","author":"Yu M","year":"2020","unstructured":"Yu M, Gong ZP, Ma ZL, et al. Crk promotes proliferation, migration, invasion of laryngeal squamous cell carcinoma. Eur Rev Med Pharmacol Sci. 2020;24(10):5473-5480.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"e_1_3_5_26_2","doi-asserted-by":"publisher","DOI":"10.3390\/cells10040739"},{"key":"e_1_3_5_27_2","doi-asserted-by":"publisher","DOI":"10.2741\/4223"},{"key":"e_1_3_5_28_2","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.14128"},{"key":"e_1_3_5_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcmgh.2018.08.007"},{"key":"e_1_3_5_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbi.2020.109246"},{"key":"e_1_3_5_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2018.11.029"},{"key":"e_1_3_5_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgr.2019.02.004"},{"key":"e_1_3_5_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.114395"},{"issue":"2","key":"e_1_3_5_34_2","first-page":"132","article-title":"Research progress of application of E-cadherin, N-cadherin and vimentin in tumor metastasis","volume":"28","author":"Li M","year":"2016","unstructured":"Li M, Wu JB, Zhang PT. Research progress of application of E-cadherin, N-cadherin and vimentin in tumor metastasis. Cancer Research and Clinic. 2016;28(2):132-136.","journal-title":"Cancer Research and Clinic"}],"container-title":["Integrative Cancer Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/15347354261487221","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/15347354261487221","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/15347354261487221","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T23:46:18Z","timestamp":1789170378000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/15347354261487221"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":33,"alternative-id":["10.1177\/15347354261487221"],"URL":"https:\/\/doi.org\/10.1177\/15347354261487221","relation":{},"ISSN":["1534-7354","1552-695X"],"issn-type":[{"value":"1534-7354","type":"print"},{"value":"1552-695X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9]]},"article-number":"15347354261487221"}}